BioPharmSignal logoBioPharmSignal

Biotech News

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026

Krystal Biotech (KRYS)Krystal BiotechEarnings

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the open of U.S. markets.

Related news

CAPRCapricor Therapeutics2026-11-03 14:00 EST

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10

ETONEton Pharmaceuticals2026-10-29 10:50 EST

Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

BCRXBioCryst Pharmaceuticals2026-10-21 20:01 EST

BioCryst to Report Third Quarter 2026 Financial Results on November 4

TSHATaysha Gene Therapies2026-11-05 13:00 EST

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

OCGNOcugen2026-10-22 11:00 EST

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

AGIOAgios Pharmaceuticals, Inc.2026-10-08 11:00 EST

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

PTCTPTC Therapeutics, Inc.2026-10-15 12:00 EST

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

CRBUCaribou2026-11-05 21:05 EST

Caribou Biosciences Reports Third Quarter 2026 Financial Results

RAREUltragenyx Pharmaceutical2026-10-27 20:05 EST

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

SRPTSarepta Therapeutics2026-10-22 12:30 EST

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

View all latest news

Krystal Biotech

HSV-1 Gene Therapy Platform Krystal Biotech develops genetic medicines using modified, non-replicating herpes simplex virus type 1 vectors. The platform supports repeat local administration and is being applied to diseases affecting skin, eye and lung tissue. VYJUVEK Franchise VYJUVEK is a topical gene therapy approved for wounds in...

Recent company news

KRYSKrystal Biotech2026-10-22 12:00 EST

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026

KRYSKrystal Biotech2026-09-03 12:00 EST

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

KRYSKrystal Biotech2026-08-03 11:00 EST

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

KRYSKrystal Biotech2026-07-23 21:00 EST

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

KRYSKrystal Biotech2026-05-18 12:00 EST

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Stock data

Close
300.25 USD
Market cap
8.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States